PharmaTher Holdings Ltd. Ketamine - News

OTCQB: PHRRF | CSE: PHRM

HOME
COMPANY
PIPELINE
INVESTORS
NEWS
CONTACT

HOME
COMPANY
PIPELINE
INVESTORS
NEWS
CONTACT

News

11/14/2022

PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience

11/1/2022

PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome

10/5/2022

PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease

9/29/2022

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022

9/16/2022

PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at the MDS International Congress

9/7/2022

PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX Ketamine Patch

7/13/2022

PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders

6/29/2022

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

5/25/2022

PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO

5/5/2022

PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs

4/25/2022

PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

4/12/2022

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs

3/23/2022

PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease

2/16/2022

PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

2/1/2022

PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus

Archives

September 2022
July 2022
June 2022
May 2022
April 2022
March 2022
February 2022
January 2022
December 2021
November 2021
October 2021
September 2021
August 2021
July 2021
June 2021
May 2021
April 2021
March 2021
February 2021
January 2021
December 2020
November 2020
October 2020

Categories

COMPANY / RESEARCH / INVESTORS / NEWS / CONTACT

Publicly-traded on the OTCQB: PHRRF and CSE: PHRM

© COPYRIGHT 2022. PharmaTher Holdings Ltd. ALL RIGHTS RESERVED.